Intended for Healthcare Professionals Only
*Trulicity is not indicated for weight loss, and weight change was a secondary endpoint in clinical trials.
1. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 Diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 ; 394:121-130.
The presentation itself will last around 20 minutes with the opportunity for Q&A at the end.
This webinar has been developed, organised and funded by Eli Lilly and Company. Trulicity (dulaglutide) will be discussed at this webinar. The calendar notification is for the sole use of the intended recipients and should not be forwarded.
Trulicity®and Lilly are registered trademarks of Eli Lilly and Company
© 2020 Eli Lilly and Company. All rights reserved.
To access the Trulicity Prescribing Information please click the following link: Trulicity Prescribing Information
PP-DG-GB-0572 March 2020
Adverse events and product complaints should be reported. Reporting forms and further information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446._1590978556122